Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that its Board of Directors has appointed Dr. Ivan Trifunovich as the company’s President and Chief Executive Officer. Dr. Trifunovich has served as a senior consultant to the Helicos Board of Directors and was elected to serve as Executive Chairman of the Board of Helicos on September 15, 2010. Ron Lowy, who stepped in as CEO at the board’s request will return to his role as a board member. Helicos today also announced the launch of a technology licensing program for its Single Molecule Sequencing Platform. Commenting on behalf of the Helicos Board of Directors, company’s co-founder Stan Lapidus said, “As a result of hard work by Ron and the Helicos management team the HeliScope sequencing platform has continued to advance in performance and applications, while the Company’s intellectual property portfolio has been significantly strengthened. We appreciate Ron’s leadership during the past two years and look forward to his continued contributions on the Board.” “I am excited to take over the leadership of Helicos during this critical time as we introduce our technology licensing program,” said Dr. Trifunovich. “We intend to create the maximum value from our strong intellectual property portfolio in single molecule sequencing, which we consider to be an absolute requirement for anyone competing in the rapidly growing next-generation, single molecule sequencing market.” “Helicos was the first to invent and market single molecule sequencing technology and has established a comprehensive patent estate with the earliest priority dates in the field,” continued Dr. Trifunovich. “We are pleased to announce that our foundational patents will be made available to encourage broad commercialization of genetic sequencing-by-synthesis and other related technologies. We plan to leverage this broad intellectual property estate that covers all sequencing-by-synthesis methods through licensing, partnering and enforcement strategies. Our plan is to vigorously defend our IP rights.” The Helicos licensing portfolio includes approximately 48 issued patents and 90 applications.